Guide

Is Psilocybin Legal in Colorado? Status, Law, and Access Explained

Psilocybin is decriminalized for personal use and possession by adults 21+ in Colorado, with licensed healing centers offering supervised sessions. Retail sale remains prohibited, and federal law still classifies psilocybin as Schedule I.

Last updated November 09, 2026 949-word guide Editor The Psychedelic Journal

Is Psilocybin Legal in Colorado? The Short Answer

No, psilocybin is not fully legal in Colorado, but it is decriminalized for personal use and possession by adults age 21 and over under state law. Colorado voters approved the Natural Medicine Health Act (Proposition 122) in 2022, which decriminalizes personal use, possession, and gifting of psilocybin mushrooms and certain other natural psychedelics. The law also established a regulated system for licensed "healing centers" where adults can access supervised psilocybin sessions with trained facilitators. However, retail sale and commercial distribution outside of these licensed settings remain prohibited. Importantly, psilocybin is still classified as a Schedule I controlled substance under United States federal law, meaning federal prosecution is technically possible. This article provides general information and is not legal advice.

Colorado's Psilocybin Law: What Changed with Proposition 122?

Proposition 122, also known as the Natural Medicine Health Act, was passed by Colorado voters in November 2022. The law made several key changes to the state's approach to psilocybin and other natural psychedelics:

For a deeper dive into the legal landscape, see our psychedelic law guide and briefing feed.

How Does Colorado's Approach Compare to Federal Law?

Despite Colorado's state-level reforms, psilocybin remains a Schedule I controlled substance under the United States Controlled Substances Act. Schedule I is the most restrictive category, reserved for substances with "no currently accepted medical use" and a "high potential for abuse." The U.S. Food and Drug Administration (FDA) has not approved any psilocybin-containing medicine as of 2026, though clinical trials are ongoing (see below). Federal law technically preempts state law, meaning federal authorities could prosecute psilocybin-related activities, though this is rare for personal use in states with decriminalization policies.

Colorado's reforms do not change federal law. Activities involving psilocybin may still carry federal legal risk, especially for commercial activity or interstate transport. For more on the national landscape, visit our psychedelic research landscape and legal status overview.

What Is Allowed (and Not Allowed) Under Colorado Law?

Activity Colorado Law (Prop 122) Federal Law
Personal use/possession (adults 21+) Decriminalized Illegal (Schedule I)
Gifting (not for sale) Decriminalized Illegal
Home cultivation (for personal use) Decriminalized Illegal
Retail sale/distribution Illegal Illegal
Facilitated session at licensed center Permitted (with license) Illegal (but rarely enforced if state-compliant)
Advertising psilocybin products Prohibited (per HB 26-1325, 2026) Illegal

Notably, psilocybin-containing edibles and gummies are not separately licensed retail categories; only supervised use at healing centers is permitted. MDMA and LSD remain Schedule I under both state and federal law.

How Do Healing Centers and Facilitated Psilocybin Sessions Work?

Colorado's regulated psilocybin program is centered on licensed healing centers. Adults 21 and older can access psilocybin in these centers under the guidance of trained facilitators. The process typically involves screening, preparation, administration of psilocybin in a controlled setting, and post-session integration support. The Division of Professions and Occupations is responsible for licensing facilitators and centers, ensuring adherence to safety, training, and ethical standards.

Retail sales of psilocybin mushrooms or products outside this system are not permitted. The law is designed to support therapeutic, not recreational, use. For more on how these programs operate, see our comprehensive guides and how to access psychedelic therapy.

What About Research, FDA Approval, and Future Changes?

Psilocybin is the subject of ongoing clinical research, with several Phase 3 trials underway. For example, Compass Pathways' COMP360 program and Usona Institute's IPR001 are both in advanced stages for treatment-resistant depression and major depressive disorder. In late 2026, Compass Pathways submitted a New Drug Application (NDA) to the FDA for psilocybin therapy in depression, marking a potential milestone for future medical approval. However, as of now, no psilocybin product has FDA approval, and its use remains limited to research or state-level programs like Colorado's.

Colorado's law also provides for review of additional psychedelics (DMT, ibogaine, mescaline) for possible inclusion in the therapeutic program after 2026. Recent legislation (HB 26-1325, effective August 2026) further regulates advertising, sales, and research pilots, including a new ibogaine research initiative.

For ongoing updates on law, policy, and research, see our briefing feed and research landscape.

Key Takeaways and Next Steps